These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Su C; Lewis JD; Goldberg B; Brensinger C; Lichtenstein GR Gastroenterology; 2007 Feb; 132(2):516-26. PubMed ID: 17258720 [TBL] [Abstract][Full Text] [Related]
69. Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis. Okuyama Y; Andoh A; Nishishita M; Fukunaga K; Kamikozuru K; Yokoyama Y; Ueno Y; Tanaka S; Kuge H; Yoshikawa S; Sugahara A; Anami E; Munetomo Y; Watanabe C; Fujiyama Y; Matsumoto T Scand J Gastroenterol; 2013 Apr; 48(4):412-8. PubMed ID: 23356660 [TBL] [Abstract][Full Text] [Related]
70. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Higgins PD; Leung J; Schwartz M; Mapili J; Wren PA; Zimmermann EM Aliment Pharmacol Ther; 2007 Feb; 25(3):333-42. PubMed ID: 17269991 [TBL] [Abstract][Full Text] [Related]
71. Histological healing after infliximab induction therapy in children with ulcerative colitis. Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025 [TBL] [Abstract][Full Text] [Related]
72. Bowel ultrasound and mucosal healing in ulcerative colitis. Parente F; Molteni M; Marino B; Colli A; Ardizzone S; Greco S; Sampietro G; Gallus S Dig Dis; 2009; 27(3):285-90. PubMed ID: 19786753 [TBL] [Abstract][Full Text] [Related]
73. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Brandse JF; Bennink RJ; van Eeden S; Löwenberg M; van den Brink GR; DʼHaens GR Inflamm Bowel Dis; 2016 Jun; 22(6):1384-90. PubMed ID: 26978724 [TBL] [Abstract][Full Text] [Related]
74. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Feagins LA; Melton SD; Iqbal R; Dunbar KB; Spechler SJ Inflamm Bowel Dis; 2013 Jun; 19(7):1477-82. PubMed ID: 23702713 [TBL] [Abstract][Full Text] [Related]
75. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Walsh A; Palmer R; Travis S Gastrointest Endosc Clin N Am; 2014 Jul; 24(3):367-78. PubMed ID: 24975528 [TBL] [Abstract][Full Text] [Related]
76. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD007571. PubMed ID: 25105240 [TBL] [Abstract][Full Text] [Related]
77. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Kim JH; Cheon JH; Park Y; Lee HJ; Park SJ; Kim TI; Kim WH Scand J Gastroenterol; 2016 Sep; 51(9):1069-74. PubMed ID: 26895215 [TBL] [Abstract][Full Text] [Related]
78. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Shi HY; Chan FKL; Higashimori A; Kyaw M; Ching JYL; Chan HCH; Chan JCH; Chan AWH; Lam KLY; Tang RSY; Wu JCY; Sung JJY; Ng SC Gastrointest Endosc; 2017 Dec; 86(6):1139-1146.e6. PubMed ID: 28713062 [TBL] [Abstract][Full Text] [Related]
79. Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. Ma C; MacDonald JK; Nguyen TM; Chang J; Vande Casteele N; Feagan BG; Jairath V Aliment Pharmacol Ther; 2022 Jan; 55(2):178-190. PubMed ID: 34821404 [TBL] [Abstract][Full Text] [Related]
80. Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Maunder RG; Greenberg GR Inflamm Bowel Dis; 2004 Sep; 10(5):632-6. PubMed ID: 15472526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]